The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Open accessAbstract
BACKGROUND: In our institute in Marseille, France, we initiated early and massive screening for coronavirus disease 2019 (COVID-19). Hospitalization and early treatment with hydroxychloroquine and azithromycin (HCQ-AZ) was proposed for the positive cases. METHODS: We retrospectively report the clinical management of 3,737 screened patients, including 3,119 (83.5%) treated with HCQ-AZ (200 mg of oral HCQ, three times daily for ten days and 500 mg of oral AZ on day 1 followed by 250 mg daily for the next four days, respectively) for at least three days and 618 (16.5%) patients treated with other regimen ("others"). Outcomes were death, transfer to the intensive care unit (ICU), ≥10 days of hospitalization and viral shedding. RESULTS: The patients' mean age was 45 (sd 17) years, 45% were male, and the case fatality rate was 0.9%. We performed 2,065 low-dose computed tomography (CT) scans highlighting lung lesions in 592 of the 991 (59.7%) patients with minimal clinical symptoms (NEWS score = 0). A discrepancy between spontaneous dyspnoea, hypoxemia and lung lesions was observed. Clinical factors (age, comorbidities, NEWS-2 score), biological factors (lymphocytopenia; eosinopenia; decrease in blood zinc; and increase in D-dimers, lactate dehydrogenase, creatinine phosphokinase, troponin and C-reactive protein) and moderate and severe lesions detected in low-dose CT scans were associated with poor clinical outcome. Treatment with HCQ-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11-0.27), decreased risk of hospitalization ≥10 days (odds ratios 95% CI 0.38 0.27-0.54) and shorter duration of viral shedding (time to negative PCR: HR 1.29 1.17-1.42). QTc prolongation (>60 ms) was observed in 25 patients (0.67%) leading to the cessation of treatment in 12 cases including 3 cases with QTc> 500 ms. No cases of torsade de pointe or sudden death were observed. CONCLUSION: Although this is a retrospective analysis, results suggest that early diagnosis, early isolation and early treatment of COVID-19 patients, with at least 3 days of HCQ-AZ lead to a significantly better clinical outcome and a faster viral load reduction than other treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
Self-citationRetractedDavido, B., Lansaman, T., Bessis, S., Lawrence, C., Alvarez, J., Mascitti, H., Bouchand, F., Moine, P., Perronne, V., Gal, A. L., et al. (2020) · medRxiv · doi:10.1101/2020.05.05.20088757 · Cited by 19
RetractedZhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587 · cited 1×
“9%), the number of covariates to be included in multivariate analyses was a priori limited to three variables: previous health status (modified Charlson combined comorbidity index) [22], severity of the disease (NEWS-2 score) and treatment (HCQ-AZ for at least 3 days).”
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775 · cited 12×
“Outcomes were death, transfer to the intensive care unit (ICU), �10 days of hospitalization and viral shedding.”
InfluentialCase-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy
Onder, G., Rezza, G., & Brusaferro, S. (2020) · JAMA · doi:10.1001/jama.2020.4683 · Cited by 4,171 · cited 1×
“8 and 19% in Italy, in grand Est region (France), in Ile de France region (France) and in China, respectively (Table 6) [23].”
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D. K., Kubin, C., Barr, R. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012410 · Cited by 1,625 · cited 2×
“Conversely, in a recent observational study, patients treated with HCQ showed no difference regarding risk of death or intubation compared with patients under other treatments [17].”
Incidence of venous thromboembolism in hospitalized patients with COVID‐19
Middeldorp, S., Coppens, M., van Haaps, T. F., Foppen, M., Vlaar, A. P., Müller, M. C. A., Bouman, C. C. S., Beenen, L. F. M., Kootte, R. S., Heijmans, J., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14888 · Cited by 1,447
Remdesivir for the Treatment of Covid-19 — Preliminary Report
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2022236 · Cited by 1,396
Rosenberg, E. S., Dufort, E. M., Udo, T., Wilberschied, L. A., Kumar, J., Tesoriero, J., Weinberg, P., Kirkwood, J., Muse, A., DeHovitz, J., et al. (2020) · JAMA · doi:10.1001/jama.2020.8630 · Cited by 1,156
Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3541136 · Cited by 898
Evidence for Health Decision Making — Beyond Randomized, Controlled Trials
Frieden, T. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1614394 · Cited by 770
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Sevestre, J., Mailhe, M., Doudier, B., Aubry, C., Amrane, S., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101663 · Cited by 765
Self-citationHolm, J. C., Nowicka, P., Farpour-Lambert, N. J., O'Malley, G., Hassapidou, M., Weiss, R., & Baker, J. L. (2014) · Obesity Facts · doi:10.1159/000365773 · Cited by 592
Mahévas, M., Tran, V.-T., Roumier, M., Chabrol, A., Paule, R., Guillaud, C., Fois, E., Lepeule, R., Szwebel, T.-A., Lescure, F.-X., et al. (2020) · BMJ · doi:10.1136/bmj.m1844 · Cited by 566
Million, M., Lagier, J.-C., Gautret, P., Colson, P., Fournier, P.-E., Amrane, S., Hocquart, M., Mailhe, M., Esteves-Vieira, V., Doudier, B., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101738 · Cited by 469
Self-citationZeng, Q.-L., Yu, Z.-J., Gou, J.-J., Li, G.-M., Ma, S.-H., Zhang, G.-F., Xu, J.-H., Lin, W.-B., Cui, G.-L., Zhang, M.-M., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa228 · Cited by 330
Andreani, J., Le Bideau, M., Duflot, I., Jardot, P., Rolland, C., Boxberger, M., Wurtz, N., Rolain, J.-M., Colson, P., La Scola, B., et al. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104228 · Cited by 319
Self-citationThe mystery of the pandemic's ‘happy hypoxia’
Couzin-Frankel, J. (2020) · Science · doi:10.1126/science.368.6490.455 · Cited by 267
Liao, X., Wang, B., & Kang, Y. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05954-2 · Cited by 266
Treating COVID-19 with Chloroquine
Huang, M., Tang, T., Pang, P., Li, M., Ma, R., Lu, J., Shu, J., You, Y., Chen, B., Liang, J., et al. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa014 · Cited by 251
Carlucci, P. M., Ahuja, T., Petrilli, C., Rajagopalan, H., Jones, S., & Rahimian, J. (2020) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001250 · Cited by 198
Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19
Yu, B., Li, C., Chen, P., Zhou, N., Wang, L., Li, J., Jiang, H., & Wang, D.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1732-2 · Cited by 161
Zhang, T., Sun, L. X., & Feng, R. E. (2020) · PubMed · doi:10.3760/cma.j.cn112147-20200311-00312 · Cited by 121
Katzen, J. B., Kohn, R. A., Houk, J. L., & Ison, M. G. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy860 · Cited by 105
Risch, H. A. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa093 · Cited by 104
High-profile coronavirus retractions raise concerns about data oversight
Ledford, H. K., & Noorden, R. V. (2020) · Nature · doi:10.1038/d41586-020-01695-w · Cited by 88
Million, M., Gautret, P., Colson, P., Roussel, Y., Dubourg, G., Chabrière, É., Honoré, S., Rolain, J., Fenollar, F., Fournier, P., et al. (2020) · New Microbes and New Infections · doi:10.1016/j.nmni.2020.100709 · Cited by 67
Self-citationEdouard, S., Colson, P., Melenotte, C., Pinto, F. D., Thomas, L., Scola, B. L., Million, M., Tissot‐Dupont, H., Gautret, P., Stein, A., et al. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04104-2 · Cited by 45
Self-citationMaking decisions to mitigate COVID-19 with limited knowledge
Zhang, W., & Qian, B.-Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30280-2 · Cited by 24
Gautret, P., & Raoult, D. (2020) · New Microbes and New Infections · doi:10.1016/j.nmni.2020.100714 · Cited by 6
Self-citation
Cited by
Fiolet, T., Guihur, A., Rebeaud, M. E., Mulot, M., Peiffer-Smadja, N., & Mahamat-Saleh, Y. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.08.022 · Cited by 306
Gheibi (2021) · doi:10.4103/1995-7645.318304 · Cited by 80
Metadata
- Authors
- Lagier, J.-C., Million, M., Gautret, P., Colson, P., Cortaredona, S., Giraud-Gatineau, A., Honoré, S., Gaubert, J.-Y., Fournier, P.-E., Tissot-Dupont, H., Chabrière, E., Stein, A., Deharo, J.-C., Fenollar, F., Rolain, J.-M., Obadia, Y., Jacquier, A., La Scola, B., Brouqui, P., Drancourt, M., Parola, P., Raoult, D., Amrane, S., Aubry, C., Bardou, M., Berenger, C., Camoin-Jau, L., Cassir, N., Decoster, C., Dhiver, C., Doudier, B., Edouard, S., Gentile, S., Guillon-Lorvellec, K., Hocquart, M., Levasseur, A., Mailhe, M., Ravaux, I., Richez, M., Roussel, Y., Seng, P., Tomei, C., & Zandotti, C.
- Venue
- Travel Medicine and Infectious Disease
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 36
- Pages
- 101791
- ISSN
- 1477-8939 (ISSN-L)
- OpenAlex
- W3037845546
- Cited by
- 254
- References
- 37
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.